EMA Authorised: Xoterna Breezhaler (indacaterol;glycopyrronium bromide) — Novartis Europharm Limited

View source ↗

Summary

EMA authorized Xoterna Breezhaler, a fixed-dose inhalation combination of indacaterol and glycopyrronium bromide, for chronic obstructive pulmonary disease, by …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Xoterna Breezhaler (indacaterol; glycopyrronium bromide)

Snippet

Status: Authorised. Therapeutic area: Pulmonary Disease, Chronic Obstructive. MAH: Novartis Europharm Limited. Decision date: 24/07/2025